Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review  

作　　者：Joe John Vattakatuchery Renjith Kurien 

机构地区：[1]5 Boroughs Partnership NHS Foundation Trust,Warrington WA28WA,United Kingdom

出　　处：《World Journal of Psychiatry》2013年第3期62-64,共3页世界精神病学杂志

摘　　要：Huntington's disease(HD) is a neurodegenerative disease associated with cognitive deficits. Cognitive dysfunction may be present in the early stages of the disease, even before the onset of motor symptoms. The cognitive dysfunction includes executive dysfunction, psychomotor symptoms, visuospatial deficits, perceptual deficits, memory loss and difficulty learning new skills. Acetylcholinesterase inhibitors have shown good effect in the treatment of other types of dementia and it is postulated that it might delay cognitive decline in HD. We reviewed the evidence for Acetylcholinesterase inhibitors in the treatment of cognitive decline and dementia associated with Huntington's disease. We identified 6 articles that investigated the role of Acetylcholinesterase inhibitors for treatment of cognitive deficits in Huntington's disease. Following the review, the authors concluded that there is limited evidence for the use of Acetylcholinesterase inhibitors for cognitive impairment in HD.Huntington's disease(HD) is a neurodegenerative disease associated with cognitive deficits. Cognitive dysfunction may be present in the early stages of the disease, even before the onset of motor symptoms. The cognitive dysfunction includes executive dysfunction, psychomotor symptoms, visuospatial deficits, perceptual deficits, memory loss and difficulty learning new skills. Acetylcholinesterase inhibitors have shown good effect in the treatment of other types of dementia and it is postulated that it might delay cognitive decline in HD. We reviewed the evidence for Acetylcholinesterase inhibitors in the treatment of cognitive decline and dementia associated with Huntington's disease. We identified 6 articles that investigated the role of Acetylcholinesterase inhibitors for treatment of cognitive deficits in Huntington's disease. Following the review, the authors concluded that there is limited evidence for the use of Acetylcholinesterase inhibitors for cognitive impairment in HD.

关 键 词：Huntington’s disease Huntington’s DEMENTIA Cognitive deficits ACETYLCHOLINESTERASE INHIBITORS DONEPEZIL RIVASTIGMINE GALANTAMINE 

分 类 号：R749[医药卫生—神经病学与精神病学]